Keyword: Boehringer Ingelheim
Prime Therapeutics plans to examine the total healthcare costs for Boehringer Ingelheim's SGLT2 drug Jardiance versus the competition.
The march to Cannes Health has begun with the announcement of the two jury presidents who will preside over the panels that judge the pharma and health & wellness categories.
BI's Gilotrif is up against some stiff competition in the EGFR lung cancer space. But this week, it snagged a label update that will widen its reach.
Takeda offloaded cancer assets, AstraZeneca formed drug discovery JV in China, Biocon's Herceptin biosimilar plant cleared FDA.
A new study shows SGLT2 diabetes drugs can cut the rate of major cardiovascular events in patients new to treatment.
After a rare decline last month, AbbVie's Humira reclaimed its title as top advertised drug on TV with more than $40 million in spending.
New research takes a wide look at the strategy of "evergreening," or adding new patents to extend a drug's exclusivity.
Two new Novo Nordisk ads seem to be typical pharma company spots with middle-aged couples strolling happily along, until they aren't.
Eli Lilly is moving to a new marketing model to manage expenses, but will ad agencies lose work as Lilly looks to bring more services in-house?
Boehringer Ingelheim’s latest campaign for Spiriva Respimat features a "real" bear hugging a sufferer, simulating the crush of asthma symptoms.